Project Grant R01AG087809
Award Date
8/15/24
Completion Date
6/30/29
Dollars Obligated
$1.4M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,543,226 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a randomized controlled trial assessing the effects of SGLT2 inhibitors on coronary flow reserve and epicardial adipose tissue among women living with HIV. The goal is to identify novel interventions to address the increased risk of myocardial...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This $383,750 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research by the University of Nebraska Medical Center (UNMC) to explore the molecular, neuro-immune and behavioral changes that occur during HIV-associated progressive aging using a long-term humanized mouse model. The goal is to determine how HIV latency and antiretroviral therapy (ART) contribute to premature aging, referred to as "LAAGING", and the associated...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) federal grant program, will explore the therapeutic effects of microglia depletion and repopulation (MGDR) on mitigating hand and neuropsychiatric symptoms in the context of chronic HIV infection. The $880,000 award, effective from September 2024 to August 2026, will be administered by Old Dominion University (ODU) and its research foundation. The project aims to investigate the impacts of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...
This federal Project Grant award of $3,343,725 from the National Institute on Aging (CFDA 93.866 Aging Research) supports research by The Spaulding Rehabilitation Hospital Corporation investigating the opposing effects of skeletal muscle extracellular matrix aging and muscle activity on extracellular vesicle promotion of muscle regeneration. The research aims to mechanistically understand how age-related changes in the muscle extracellular matrix impact the molecular signatures of muscle-derived...
This federal Project Grant award from the National Institute on Minority Health and Health Disparities (CFDA 93.307 Minority Health and Health Disparities Research) provides $855,233 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to understand the relationship between individual, social, and structural determinants of health, mobility, and HIV outcomes among adolescents and young adults living with HIV in Tennessee. The award supports a 5-year study that...
This $644,864 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports preclinical studies by Ridgeline Therapeutics LLC, a Houston-based biotech company, to evaluate the efficacy of their lead compound RT-002 in preventing and reversing disuse-induced muscle atrophy in aging rat models. Specifically, the project aims to determine if RT-002 treatment can mitigate the loss of muscle mass and strength during muscle disuse, as well as improve the rate...
This Project Grant award, valued at $244,328.00 and provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 Allergy and Infectious Diseases Research, will support research to investigate the impact of in-utero HIV and antiretroviral (ARV) exposure on the placenta and birth weight. The study aims to compare placental histologic abnormalities based on ARV levels in neonatal hair and maternal dried blood spots, as well as determine the effects of...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $392,709 to the University of California, Los Angeles (UCLA) to analyze the impact of natural aging and accelerated aging due to HIV-1 infection on humoral immunity, particularly in the gastrointestinal tract. The primary objectives are to: 1) Determine age-related B cell senescence in the gut-associated lymphoid tissue (GALT) versus peripheral blood of people with and without HIV, and...